CN109239372A - Abo blood group antigen detectability verifies product and its application - Google Patents
Abo blood group antigen detectability verifies product and its application Download PDFInfo
- Publication number
- CN109239372A CN109239372A CN201811300149.6A CN201811300149A CN109239372A CN 109239372 A CN109239372 A CN 109239372A CN 201811300149 A CN201811300149 A CN 201811300149A CN 109239372 A CN109239372 A CN 109239372A
- Authority
- CN
- China
- Prior art keywords
- antigen
- red blood
- blood cell
- abo
- weak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to the methods and its kit of a kind of detectability for assessing abo blood group antigen, the kit includes the Quality Control red blood cell of weak A, B antigen and the red blood cell for mixing ABO poor antigen, the preparation method of the Quality Control red blood cell of weak A, B antigen is: by preparing a series of red blood cells containing relative quantification A, B antigen, wherein proficiency testing product may be made comprising the O-shaped red blood cell of certain amount as negative control.The preparation method of mixing ABO poor antigen is: mixing O-shaped and A or Type B red blood cell by the different proportion drafted, alserver's solution is added after mixing, A or B " mixed agglutination " sample of determining yin-yang sex ratio is made, wherein may be comprising the O-shaped red blood cell of certain amount as negative control.The kit that the present invention is prepared can be used for assessing the detectability of the abo blood group antigen in laboratory of participating in the experiment.
Description
Technical field
The present invention relates to the verification technique fields of immunohematology Serologic detection ability, specifically, being that abo blood group is anti-
Former detectability verifying product and its application.
Background technique
Blood group is to typically refer to the parting of red blood cell (RBC) to the method for blood classification, according to be the surface RBC whether
There are certain heritable antigenic substances.It has been found that and have 36 kinds for the blood group system that international Blood Transfusion Association recognizes, with the mankind
Blood transfusion relationship it is most close be ABO blood group system, followed by Rh blood group system, there are also the systems such as MNS, Kell also with certain diseases
It is closely bound up.Bracket for blood grouping refers to the technology identified cell surface antigen in blood constituent.Fast and accurately blood group is reflected
Determining technology has extensive practical value to subjects such as science of heredity, medical jurisprudence, clinical medicine, therefore has important theory and reality
Trample meaning.Bracket for blood grouping is most important to transfusing blood, especially in the traumatic big bleeding of medicine, organ transplantation, neonatal hemolytic etc.,
The generation that may cause hemolytic reaction with incompatible blood group blood transfusion is caused hemolytic anemia, kidney failure, suffered a shock down to dead.
Therefore, quick, accurate, simple Shanghai can provide safeguard for rescue urgent patient, solution of emergent event.
The function of Blood Center is detection blood with the blood group of accurate judgement individual.For accurately and precisely sentencing for blood group
Disconnected is required for multinomial treatment, including blood transfusion, organ transplant and the neonatal haemolytic diseases for the treatment of.For example, a disease
People must know its blood group before receiving blood transfusion.The mispairing of the blood group of blood donor and receptor will generate serious consequence, very
To the death that will lead to receptor.In blood transfusion serology, abo blood group classification is most important one kind in erythrocyte blood type classification
Classification method.The abo blood group of people is divided primarily into four kinds: A, B, AB and O-shaped.The red blood cell of every kind of blood group carries Staphylococal Protein A respectively,
B antigen, Staphylococal Protein A and B antigen, both without Staphylococal Protein A or without B antigen.In everyone blood, there are anti-abo blood group antigens or red
The antibody of the antigen lacked in cell.Therefore, the antibody of anti-B antigen is contained in people's blood of A type blood, is contained in people's blood of Type B blood
The antibody of anti-Staphylococal Protein A, contains the antibody of anti-Staphylococal Protein A and B antigen in people's blood of O-shaped blood, both nonreactive Staphylococal Protein A in people's blood of AB type blood
Antibody also nonreactive B antigen antibody.There are the hypotypes of antigen weak expression for Human Blood Type ABO, as disease, especially white
Blood disease causes antigen to weaken, or forms mixed type antigen.Thereby it is ensured that the detection energy of weak ABO antigen and mixed type antigen
Power just can guarantee the correct identification of abo blood group.
The quality control of blood grouping reagent is necessary for the accuracy and credibility of blood group determination.Blood grouping reagent can transported
It is defeated and storage during occur specificity and/or sensitivity reduction, or during making and using caused by pollution.
In addition, existing similar quality-control product, is " the external quality assurance product " that industry, tissue or laboratory are provided, quality inspection Quality Control
Product are made of one or several human blood samples, may include normal abo blood group sample or ABO hypotype sample.Pass through hair
These samples are put to laboratory of participating in the experiment, and the testing result of recovery experiment room is analyzed, obtains the laboratory and abo blood group is examined
The assessment of survey ability.The shortcoming of this kind of external quality assurance product, be can not accurate evaluation participate in the experiment the abo blood group antigen in laboratory
Detectability.The detectability of ABO antigen is embodied in two aspects, one is for hereditary (such as ABO hypotype antigen) or disease
The detectability for the ABO poor antigen that (such as class B antigen) factor is formed；The second is for heredity or disease (as caused by leukaemia
Antigen weaken) factor formed " mixed agglutination " detectability.It is ideal for the ability of accurate evaluation these two aspects
Method is to prepare the proficiency testing product with not synantigen intensity to simulate the former, or think to be mixed in a certain ratio specific
ABO antigen negative and positive red blood cell prepare the proficiency testing product of known yin-yang sex ratio to simulate the latter.And due to mesh
Preceding ABO antigen detection external quality assurance product are taken from normal human blood, no matter normal abo blood group or use rare ABO hypotype
Sample can not control to relative quantification antigen A BO antigen intensity, also be unable to control specific ABO antigen yin-yang sex ratio, therefore
Can not accurate evaluation participate in the experiment the ABO antigen detectability in laboratory.
Chinese patent application: CN105785055B discloses a kind of detection method of the abo blood group antigen of bacterium surface.Institute
State detection method it is similar to Human Blood Type ABO antigen based on the structure of bacterial surface polysaccharides and have the active spy of blood group substance
Point is handled by bacteria adhension and the abo blood group natural antibody of people and bacterial surface polysaccharides is utilized to interact, with multi-functional
The detection of microplate reader realization bacterium surface abo blood group antigen.
Chinese patent application: CN100588719C disclose a kind of method for preparing low expression blood type antigen red blood cell and its
Application in the control of blood grouping reagent quality, the invention prepare low expression blood type using at least one epistatic immunized glucose modified enzyme
The method of the red blood cell of antigen, such as N-acetylgalactosaminase or alpha-galactosidase.
But it yet there are no report about abo blood group antigen detectability of the present invention verifying product and its application.
Summary of the invention
The first purpose of this invention is in view of the deficiencies of the prior art, to provide a kind of assessment abo blood group antigen detection energy
The kit of power.
Second object of the present invention is in view of the deficiencies of the prior art, to provide the application of mentioned reagent box.
Third object of the present invention is in view of the deficiencies of the prior art, to provide a kind of assessment abo blood group antigen detection energy
The method of power.
Fourth object of the present invention is in view of the deficiencies of the prior art, to provide the application of the above method.
To realize above-mentioned first purpose, the technical solution adopted by the present invention is that:
A kind of kit for assessing abo blood group antigen detectability, the kit include weak Staphylococal Protein A, B antigen presentation amount
A, B mixed agglutination product of different red blood cell and known poor antigen yin-yang sex ratio,
The preparation method of the different red blood cell of the poor antigen expression quantity includes the following steps:
(1) first with the glycosyl transferase for forming A or B antigen and O-shaped red blood cell is converted to A to corresponding substrate or Type B is red
Cell；
(2) by control enzyme, the content of substrate, incubation time or reaction temperature, reach the O-shaped erythrocyte surface of control and generate
The purpose of the quantity of weak A or B antigen；
(3) flow cytomery is used, weak A or B on the weak A or Type B red blood cell manually prepared is further quantitatively determined
The quantity of antigen is to get the red blood cell different to poor antigen expression quantity；
The preparation method of A, B mixed agglutination product of the known poor antigen yin-yang sex ratio includes the following steps:
The different red blood cell of the above-mentioned poor antigen expression quantity being prepared is separately added into O-shaped red blood cell, is added after mixing
Enter alserver's solution to save to get A, B mixed agglutination product of known poor antigen yin-yang sex ratio is arrived.
As a preferred embodiment of the invention, the red blood cell is human erythrocyte.
As a preferred embodiment of the invention, the glycosyl transferase includes N acetyl galactose transferase, gala
Sugared transferase；The substrate includes N acetyl galactose substrate, galactose substrate.
To realize above-mentioned second purpose, the technical solution adopted by the present invention is that:
Application of the kit as described above in assessment abo blood group antigen detectability.
To realize above-mentioned third purpose, the technical solution adopted by the present invention is that:
A method of assessment abo blood group antigen detectability, described method includes following steps:
(1) the different red blood cell of weak Staphylococal Protein A, B antigen presentation amount is prepared: first with the glycosyl transferase for forming A or B antigen
O-shaped red blood cell is converted to A or Type B red blood cell with corresponding substrate；Then by control enzyme, the content of substrate, incubation time or
Reaction temperature achievees the purpose that control the quantity that O-shaped erythrocyte surface generates weak A or B antigen；Finally examined using flow cytometer
It surveys, further quantitatively determines the quantity of weak A or B antigen on the weak A or Type B red blood cell manually prepared and expressed to get to poor antigen
Measure different red blood cells；
(2) the different red blood cell of the above-mentioned poor antigen expression quantity being prepared is used for object to be tested, and analyzed to be measured
The testing result for trying object, that is, can reach the purpose for assessing the detectability of weak ABO antigen；
(3) A, B mixed agglutination product of known poor antigen yin-yang sex ratio are prepared: by the above-mentioned poor antigen table being prepared
It is added separately to produce in O-shaped red blood cell to get to A, B mixed agglutination of known poor antigen yin-yang sex ratio up to different red blood cells is measured
Product；
(4) it is to be tested right to be used for A, B mixed agglutination product of the above-mentioned known poor antigen yin-yang sex ratio being prepared
As, and analyze the testing result of object to be tested, that is, it can reach the purpose of assessment mixed agglutination ABO antigen detectability.
As a preferred embodiment of the invention, the red blood cell is human erythrocyte.
As a preferred embodiment of the invention, the glycosyl transferase includes N acetyl galactose transferase, gala
Sugared transferase；The substrate includes N acetyl galactose substrate, galactose substrate.
As a preferred embodiment of the invention, the test method in the step (2) and step (4) includes test tube
Method and microtrabeculae agglutination.
As a preferred embodiment of the invention, weak A, B, AB antigen red blood cell is according to reagent system described in table 1
It is standby:
Table 1 prepares the reagent of weak A, B, AB antigen red blood cell
As a preferred embodiment of the invention, when the method is used to assess the detectability of abo blood group antigen
Obtained conclusion includes that can be had an impact to experimental result using the experiment test card that different vendor provides.
To realize above-mentioned 4th purpose, the technical solution adopted by the present invention is that:
Application of the method as described above in the detectability of assessment abo blood group antigen.
The invention has the advantages that:
1, nearly 200 laboratories have carried out research on probation to verifying product of the invention at home, from the result of feedback
Analysis, this method can effectively assess the ability that abo blood group antigen is detected in laboratory, especially cause to ABO hypotype, disease
ABO antigen weaken etc. abnormal conditions detectability better effect.
2, verifying product of the invention can be used for verifying or assessing immunohematology laboratory and (be engaged in erythrocyte blood type to detect
Laboratory) or professional technician abo blood group detectability.Or verifying specialized laboratory is detected in ABO antigen
In terms of ability, if meet quality requirement, assessment tool is provided.
3, method implementation of the invention is strong, and Evaluated effect is good, can overcome it is now existing can not accurate evaluation participate in the experiment reality
The problem of testing the ABO antigen detectability of room, has a good application prospect.
Detailed description of the invention
Attached drawing 1 is that the ABO hypotype test effectively test paper of constituent parts in the expression quantity different experiments of B antigen red blood cell summarizes
As a result (79).
Attached drawing 2 is the expression quantity different experiments Zhong Bu commensurate Classifying Sum result column diagram of B antigen red blood cell.
Attached drawing 3 is each method summarized results column diagram in the different experiment of the expression quantity of B antigen red blood cell.
Attached drawing 4 is to detect different proportion B-O cell mixing Board Lot in the weak ABO antigen quality-control product application experiment of mixing
As a result column diagram.
Attached drawing 5 is detection different proportion B-O mixing in same type laboratory in the weak ABO antigen quality-control product application experiment of mixing
The result column diagram of cell proportion.
Attached drawing 6 is mixed shared by the B cell of weak ABO antigen quality-control product application experiment Zhong Ge manufacturer detection different proportion mixing
The result column diagram of percentage.
Attached drawing 7 is the analysis result broken line of test tube method and microtrabeculae agglutination in the weak ABO antigen quality-control product application experiment of mixing
Figure.
Specific embodiment
The invention will be further elucidated with reference to specific embodiments.It should be understood that these embodiments are merely to illustrate this hair
It is bright rather than limit the scope of the invention.In addition, it should also be understood that, after having read the content of the invention recorded, art technology
Personnel can make various changes or modifications the present invention, and such equivalent forms equally fall within the application the appended claims and limited
Fixed range.
Embodiment 1 assesses the preparation of the kit of the detectability of abo blood group antigen
The kit of the detectability of assessment abo blood group antigen is prepared according to method as described below.
The kit includes the different red blood cell and known poor antigen yin-yang sex ratio of weak Staphylococal Protein A, B antigen presentation amount
A, B mixed agglutination product.
1, the preparation of the different red blood cell of weak Staphylococal Protein A, B antigen presentation amount
(1) items reagent described in table 1 is added, it will be O-shaped red thin with the glycosyl transferase and corresponding substrate for forming A or B antigen
Dysuria with lower abdominal colic is melted into A or Type B red blood cell；
Table 1 prepares the reagent of weak A, B, AB antigen red blood cell
(2) by changing enzyme, the content of substrate, incubation time or reaction temperature, each red blood cell is prepared respectively
Antigen presentation amount is 1*104、0.8*104、0.5*104、0.2*104、0.1*104；
(3) flow cytomery is used, weak A or B on the weak A or Type B red blood cell manually prepared is further quantitatively determined
The quantity of antigen is to get the red blood cell different to poor antigen expression quantity；
2, the preparation of A, B mixed agglutination product of known poor antigen yin-yang sex ratio
Be added 0.1% in O-shaped red blood cell respectively, 0.3%, 0.5%, 0.8%, 1.5%, 3.0%, 10%B type it is red thin
Born of the same parents are added alserver's solution and save, A, B mixed agglutination product of known poor antigen yin-yang sex ratio is made after mixing.
The applicating evaluating of the weak abo blood group antigen quality-control product of embodiment 2
One, data
1.1 general information
It participates in the experiment laboratory
From Blood Center, center blood station, comprehensive Grade A hospital, section hospital, 90 laboratories of participating in the experiment are shared, wherein 79
Family submits partial data, including Blood Center to share 12, and center blood station or comprehensive Grade A hospital share 57, and section hospital is total
There are 10.
It participates in the experiment experiment product
The 5 different amounts of B antigen red blood cells of expression prepared in embodiment 1 are selected in this experiment.
Blood group test card provides manufacturer (all in random order): gloomy more (OCD) companies difficult to understand, Bo Xun company, BioRad
(Diamed) company, GRIFOLS (Diana) company, Sanquin company
Test tube method reagent provides manufacturer (all in random order): Zhuhai Bei Suo company, Shanghai blood biotech firm, and Changchun is rich
Moral company.
1.2 are included in standard
The experiment in laboratory of participating in the experiment is completed, and the test paper in laboratory of participating in the experiment is completely effective.
Two, experimental method
By embodiment 1 be prepared participate in the experiment experiment product and corresponding test paper is issued to laboratory of respectively participating in the experiment respectively, respectively participate in the experiment
The blood group test card of manufacturer's offer is selected according to conventional test method and at random to detect the different B antigen of expression quantity in laboratory
Red blood cell, and complete corresponding test paper.
Three, experimental result
This proficiency testing recycles 90 parts of test papers altogether, and complete effectively 79 parts of test paper, experimental result is as shown in Figure 1-Figure 3,
In come from 12 parts of Blood Center；From center blood station or comprehensive 57 parts of Grade A hospital；From 10 parts of section hospital.
There is about 10% false positive phenomenon in the detection of weak ABO antigen as the result is shown；And these false positive phenomenons are concentrated
In center blood station and Grade A hospital laboratory；The reagent of different vendor also produces certain influence to the reliability of detection.
The applicating evaluating of A, B mixed agglutination product of poor antigen yin-yang sex ratio known to embodiment 3
One, data
1.1 general information
It participates in the experiment laboratory
The hospital below Blood Center, center blood station, front three synthesis, front three training, front three.Laboratory of participating in the experiment is shared
190.
It participates in the experiment experiment product
A, B mixed agglutination product of the known poor antigen yin-yang sex ratio prepared in embodiment 1 are selected in this experiment.
Blood group test card provides manufacturer (all in random order): gloomy more (OCD) companies difficult to understand, Bo Xun company, BioRad
(Diamed) company, GRIFOLS (Diana) company, Sanquin company
Test tube method reagent provides manufacturer (all in random order): Zhuhai Bei Suo company, Shanghai blood biotech firm, and Changchun is rich
Moral company.
1.2 are included in standard
The experiment in laboratory of participating in the experiment is completed, and the test paper in laboratory of participating in the experiment is completely effective.
Two, experimental method
By embodiment 1 be prepared participate in the experiment experiment product and corresponding test paper is issued to laboratory of respectively participating in the experiment respectively, respectively participate in the experiment
The blood group test card that laboratory selects manufacturer to provide according to conventional test method and at random is come poor antigen yin and yang attribute known to detecting
A, B mixed agglutination product of ratio, and complete corresponding test paper.
Three, experimental result
Effectively totally 164 parts of recycling test paper of this experiment.Analysis result such as see Fig. 4-Fig. 6, the results showed that each laboratory it
Between to the Detection capability of the quality-control product there are greatest differences, laboratory of different nature also can generate larger shadow to experimental result
It rings, wherein the detectability of front three general hospital and Blood Center is relatively higher than the experiment of center blood station and non-front three general hospital
Room, it is most important that, the reagent that different vendor provides produces bigger effect testing result.
The applicating evaluating of 4 Blood grouping distinct methods of embodiment
One, data
1.1 general information
It participates in the experiment laboratory
From Blood Center.Laboratory of participating in the experiment shares 151.
It participates in the experiment experiment product
A, B mixed agglutination product of the known poor antigen yin-yang sex ratio prepared in embodiment 1 are selected in this experiment.
Blood group test card source is as follows:
Shanghai Yu Duo Biotechnology Co., Ltd is named as manufacturer 6.
1.2 are included in standard
The experiment in laboratory of participating in the experiment is completed, and the test paper in laboratory of participating in the experiment is completely effective.
Two, experimental method
By embodiment 1 be prepared participate in the experiment experiment product and corresponding test paper is issued to laboratory of respectively participating in the experiment respectively, respectively participate in the experiment
The blood group test card that laboratory uses manufacturer 6 to provide, and wherein have 52 laboratories selection microtrabeculae agglutinations of participating in the experiment, 99
Test tube method is selected in laboratory of participating in the experiment, and to detect A, B mixed agglutination product of known poor antigen yin-yang sex ratio, and completes mutually to reply
Volume.
Blood group test method includes test tube method and microtrabeculae agglutination.
Three, experimental result
For experimental result as shown in fig. 7, in this experiment, 52 use microtrabeculae agglutination；99 use test tube method.Test tube method
It is significantly higher to the detectability of mixing weak B antigen yin-yang sex ratio.
Experiment conclusion
Through the foregoing embodiment 2 and 3 the result shows that: the factor that can generate significant impact to experimental results includes:
The blood type test card and different blood type testing methods that laboratory of different nature of participating in the experiment, different vendor provide.
Nearly 200 laboratories have carried out research on probation to verifying product of the invention at home, from the result of feedback point
Analysis, this method can effectively assess the ability that abo blood group antigen is detected in laboratory, especially caused by ABO hypotype, disease
The detectability better effect of the abnormal conditions such as ABO antigen decrease.Verifying product of the invention can be used for verifying or assessing immune
The abo blood group detectability of haematological laboratory (laboratory for being engaged in erythrocyte blood type detection) or professional technician.It can also
Think verifying specialized laboratory in terms of ABO antigen detectability, if to meet quality requirement, provide assessment tool.This
The method implementation of invention is strong, and Evaluated effect is good, can overcome it is now existing can not accurate evaluation participate in the experiment the ABO antigen in laboratory
The problem of detectability, has a good application prospect.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, without departing from the principle of the present invention, can also make several improvement and supplement, these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (10)
1. a kind of kit for assessing abo blood group antigen detectability, which is characterized in that the kit includes weak Staphylococal Protein A, B
A, B mixed agglutination product of the different red blood cell of antigen presentation amount and known poor antigen yin-yang sex ratio,
The preparation method of the different red blood cell of the poor antigen expression quantity includes the following steps:
(1) O-shaped red blood cell is converted to A or Type B red blood cell with the glycosyl transferase and corresponding substrate for forming A or B antigen first；
(2) by control enzyme, the content of substrate, incubation time or reaction temperature, reach the O-shaped erythrocyte surface of control and generate weak A
Or the purpose of B antigen levels；
(3) flow cytomery is used, weak A or B antigen on the weak A or Type B red blood cell manually prepared is further quantitatively determined
Quantity to get to the different red blood cell of poor antigen expression quantity；
The preparation method of A, B mixed agglutination product of the known poor antigen yin-yang sex ratio includes the following steps:
The different red blood cell of the above-mentioned poor antigen expression quantity being prepared is separately added into O-shaped red blood cell, is added after mixing red
Cell-preservation liquid saves to arrive A, B mixed agglutination product of known poor antigen yin-yang sex ratio.
2. kit according to claim 1, which is characterized in that the red blood cell is human erythrocyte.
3. kit according to claim 1, which is characterized in that the glycosyl transferase include N acetyl galactose transferase,
Galactosyl transferase；The substrate includes N acetyl galactose substrate, galactose substrate.
4. application of the kit described in claim 1 in the detectability of assessment abo blood group antigen.
5. a kind of method for assessing abo blood group antigen detectability, which is characterized in that described method includes following steps:
(1) the different red blood cell of weak Staphylococal Protein A, B antigen presentation amount is prepared: first with the glycosyl transferase and phase for forming A or B antigen
Answer substrate that O-shaped red blood cell is converted to A or Type B red blood cell；Then pass through control enzyme, the content of substrate, incubation time or reaction
Temperature achievees the purpose that control the quantity that O-shaped erythrocyte surface generates weak A or B antigen；Flow cytomery is finally used,
Quantitatively determine the quantity of weak A or B antigen on the weak A or Type B red blood cell manually prepared further to get poor antigen expression quantity is arrived not
Same red blood cell；
(2) the different red blood cell of the above-mentioned poor antigen expression quantity being prepared is used for object to be tested, and analyze it is to be tested right
The testing result of elephant can reach the purpose for assessing the detectability of weak ABO antigen；
(3) A, B mixed agglutination product of known poor antigen yin-yang sex ratio are prepared: by the above-mentioned poor antigen expression quantity being prepared
Different red blood cells is added separately to arrive A, B mixed agglutination product of known poor antigen yin-yang sex ratio in O-shaped red blood cell；
(4) A, B mixed agglutination product of the above-mentioned known poor antigen yin-yang sex ratio being prepared are used for object to be tested, and
The testing result of object to be tested is analyzed, that is, can reach the purpose of the detectability of assessment mixed agglutination ABO antigen.
6. method according to claim 5, which is characterized in that the red blood cell is human erythrocyte.
7. method according to claim 5, which is characterized in that the glycosyl transferase includes N acetyl galactose transferase, half
Galactosyltransferase；The substrate includes N acetyl galactose substrate, galactose substrate.
8. method according to claim 5, which is characterized in that the test method in the step (2) and step (4) includes examination
Tube method and microtrabeculae agglutination.
9. method according to claim 5, which is characterized in that the method is for when assessing abo blood group antigen detectability
Obtained conclusion includes that can be had an impact to experimental result using the experiment test card that different vendor provides.
10. application of claim 5 the method in assessment abo blood group antigen detectability.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811300149.6A CN109239372A (en) | 2018-11-02 | 2018-11-02 | Abo blood group antigen detectability verifies product and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811300149.6A CN109239372A (en) | 2018-11-02 | 2018-11-02 | Abo blood group antigen detectability verifies product and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109239372A true CN109239372A (en) | 2019-01-18 |
Family
ID=65080452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811300149.6A Pending CN109239372A (en) | 2018-11-02 | 2018-11-02 | Abo blood group antigen detectability verifies product and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109239372A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1571927A (en) * | 2001-10-16 | 2005-01-26 | 科威精密有限公司 | Sensitivity controls for blood serology prepared from modified cells |
| WO2005121322A1 (en) * | 2004-06-11 | 2005-12-22 | Kiwi Ingenuity Limited | Enzymatic modification of cell-surface h antigen by glycosyltransferases |
| CN1751130A (en) * | 2003-02-17 | 2006-03-22 | 科威精密有限公司 | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
| CN105785055A (en) * | 2016-05-19 | 2016-07-20 | 郑州轻工业学院 | Detection method for bacterial surface ABO blood group antigens |
| CN106483303A (en) * | 2015-08-24 | 2017-03-08 | 北京中检安泰诊断科技有限公司 | Human blood types detection kit and preparation method thereof |
-
2018
- 2018-11-02 CN CN201811300149.6A patent/CN109239372A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1571927A (en) * | 2001-10-16 | 2005-01-26 | 科威精密有限公司 | Sensitivity controls for blood serology prepared from modified cells |
| CN1751130A (en) * | 2003-02-17 | 2006-03-22 | 科威精密有限公司 | Preparation of red blood cells with a modified level of blood group antigen expression and their use in the quality control of blood typing reagents |
| WO2005121322A1 (en) * | 2004-06-11 | 2005-12-22 | Kiwi Ingenuity Limited | Enzymatic modification of cell-surface h antigen by glycosyltransferases |
| CN106483303A (en) * | 2015-08-24 | 2017-03-08 | 北京中检安泰诊断科技有限公司 | Human blood types detection kit and preparation method thereof |
| CN105785055A (en) * | 2016-05-19 | 2016-07-20 | 郑州轻工业学院 | Detection method for bacterial surface ABO blood group antigens |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5154445B2 (en) | Multiplex detection of anti-erythrocyte alloantibodies | |
| EP1059534B1 (en) | Determination of reverse ABO blood group | |
| Waller et al. | Study of rheumatoid factor in a normal population | |
| TWI475229B (en) | A reagent group for transfusion test and its test method | |
| CN102175877A (en) | Method for trace, fast and accurate detection of human erythrocyte antigen and antibodies in serum | |
| CN107643409A (en) | A kind of blood group antigens chip and its application in red blood cell accident antibody test | |
| Quinn et al. | Blood: tests used to assess the physiological and immunological properties of blood | |
| Chang et al. | Evaluation of Erytra® fully automated analyser for routine use in transfusion laboratory | |
| CN102879560A (en) | Method for accurately and rapidly detecting antigens and antibodies in human serum in trace mode | |
| CN107202898A (en) | Kit for Shanghai irregular antibody | |
| CN107976397A (en) | The preparation and its application of a kind of hemolytic agent | |
| CN113156143A (en) | Blood group irregular antibody specificity identification method and reagent thereof | |
| CN109239372A (en) | Abo blood group antigen detectability verifies product and its application | |
| Holburn et al. | The UK national external quality assessment scheme in blood group serology. ABO and D grouping, antibody screening, direct antiglobulin test and antibody identification 1984–1985 | |
| CN102221619A (en) | ELISA (Enzyme-Linked Immuno Sorbent Assay) detection method and kit of cryptosporidium virus capsid protein antibody | |
| US5143826A (en) | Method for identifying feline blood type B | |
| Tahir et al. | Haematological Manifestations in Children with Extended Drug-Resistant Salmonella Typhi Infections in a Tertiary Care Hospital | |
| Kharshandi et al. | A comparative study between gel card method and manual method for Coomb’s test | |
| Miles | The case for unit notation in specifying the agglutinating potency of standard antisera | |
| CN109030486A (en) | A kind of Test for Bacterial Endotoxins of hemoglobin samples | |
| CN113219183B (en) | Liquid rubber blood type detection card, preparation method and blood type detection system | |
| KR102609257B1 (en) | An apparatus for testing abo antibody and method thereof | |
| CN110736832B (en) | Composition for identifying spectrum cells by using antibody | |
| CN101470120A (en) | Electro-chemical method and system for human blood type detection | |
| Mohn et al. | An Inherited Blood Group A Variant in the Finnish Population: I. Basic Characteristics 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |
|
| RJ01 | Rejection of invention patent application after publication |